Immunovant Inc (IMVT) is trading -8% lower at $5.715 today. While it's generally been a somewhat pessimistic day for this part of the market, the company is wavering behind it's peers in the Health Care sector.

IMVT released its quarterly earnings data on Wednesday, June 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). Immunovant Inc has been trading between a 52-week high of $9.54 and a 52-week low of $3.15. The stock has a market cap of $666 Million.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Benzinga 08-22-22

Immunovant: Q1 Earnings Insights
Benzinga 08-05-22

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
GlobeNewswire 08-05-22

HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
PR Newswire Asia (English) 07-29-22

Immunovant to begin pivotal trials for batoclimab for thyroid eye disease in 2H 2022
Seeking Alpha 06-08-22